OLYMPUS Investor Day 2018 (1)

from the beginning

Overview

Presenter：

Hiroyuki Sasa
Representative Director, President

@Disclaimers

@Key Points for Today

@Olympus’s Endoscope Business Medical business inemerging-market

@Olympus’s Endoscope Business

@Medical business in Emerging-market-1

@Medical business in Emerging-market-2

@Review and the forecast for FY2021

@Review-1

@Review-2

@Projections for March 2021 Period

@Measures Aimed at Projections for March 2021 Period

@Initiatives for Achieving Sustainable Growth

@Initiatives for Achieving Sustainable Growth: Review of Current Situation

@Initiatives for Achieving Sustainable Growth: Establish Global Management Practices

@Initiatives for Achieving Sustainable Growth: Formulation of New Management Principles

@Initiatives for Achieving Sustainable Growth: Formulation of New Management Principles

@Initiatives for Achieving Sustainable Growth: Improve Management Speed and Efficiency

@Initiatives for Achieving Sustainable Growth: Achieve Medical Innovation

@OLYMPUS

Scientific Solutions Business(SSBU)

@Initiatives Planned to Achieve 16CSP Targets

Imaging Business Unit (IMBU)

@Initiatives Planned to Achieve 16CSP Targets

@OLYMPUS

Medical Business Strategy

Presenter：

Akihiro Taguchi
Business Management Officer, Medical Business

@Disclaimers

@Directives for Medical Business Strategy(1)

@Directives for Medical Business Strategy(2)

@Directives for Medical Business Strategy (3): Investment Policies

@Priority Measures (1)

@Priority Measures (2)

@Changes in the Operating Environment (Disparities from Initial 16CSP Outlook)

@Review(3 business fields: Endoscopes, Surgical, EndoTherapy)

@Review (5BUs) and CAGR forecast

@Outlook for the Term to FY2021

@Issues and Measures

@Gastrointestinal and Respiratory Business Unit （GIRBU）

@Strategic Initiatives for Each Business Unit: GIRBU

@Progress in Addressing Strategic Challenges (Business Strategies) (1/2)

@Future Actions

@Efforts to mitigate infection risks

@GI&R: Infection risk mitigation in reusable endoscopes

@GI&R: Single-use endoscope

@GI&R：Olympus’ view on Benefits of Reusable endoscopes

@General Surgery Business Unit (GSBU)

@Strategic Initiatives for Each Business Unit: GSBU

@Progress in Addressing Strategic Challenges (Business Strategies）

@Progress and Issues in Addressing Strategic Challenges (Business Strategies）-1

@Progress and Issues in Addressing Strategic Challenges (Business Strategies）-2

@Progress and issues in Addressing Strategic Challenges (Business Strategies）-3

@Progress and issues in Addressing Strategic Challenges (Business Strategies）-4

@Future direction to archive 16CSP targets

@Urology/ Gynecology Business Unit (UGBU)

@Strategic Initiatives for Each Business Unit: UGBU

@Urology/ Gynecology Business Unit: The three fields constituting urology

@Progress on Business Issues (Business Strategy)

@Urology/ Gynecology Business Unit -1

@Urology/ Gynecology Business Unit -2

@Directives for Medical Business Strategy(1)

@OLYMPUS

US Medical Business Presentation

Presenter：

Nacho Abia
Executive Officer
Regional Representative Officer, Americas

@Disclaimer

@Agenda

@Our Story in the Americas

@Olympus Corporation of the Americas Overview

@Olympus Corporation of the Americas Financial Impact

@Olympus Corporation of the Americas Structure

@Our Groundwork for Success

@Investments in Our Business

@Investments Overview (April 2013 - March 2018)

@Investments in Business Development

@Investments in Emerging Markets

@LAD Growth Potential

@Efficiency

@Globalization/Organizational Structure/Business Process Reengineering/E3/One Olympus

@People

@True to LIFE/Culture and Employee Experience/Core Values/Talent Development/Integrity

@Doing Business the Right Way

@Our Medical Business

@U.S. Medical Business Net Sales Growth (July 2017 - July 2018)

@U.S. Healthcare Industry Trends

@U.S. Healthcare Industry Trends Impacting Our Business

@Complete Solution Partner

@GI & Respiratory Business - Looking Forward

@Surgical Business - Looking Forward

@In Summary

@OLYMPUS

Q&A